Biogen’s quarterly results miss expectations amid slow launch of Alzheimer’s treatment

Biogen on Tuesday reported fourth-quarter results that fell short of Wall Street expectations as uptake of its newer drugs failed to offset declining multiple-sclerosis product sales.

Previous post Hasbro’s stock plunges toward worst day in four years after profit falls well below expectations
Next post Shopify logs earnings beat, but its stock retreats